Glucose in the urine is usually elevated with dagliflozin tablets. Dagliflozin tablets are a sodium-glucose co-transporter protein 2 inhibitor, a newly emerged hypoglycemic drug in recent years, which is mainly used for patients with type 2 diabetes, and is not applicable to patients with type 1 diabetes. The main mechanism of this drug is to inhibit the reabsorption of glucose after glomerular filtration, thereby increasing the excretion of urinary glucose to achieve the purpose of lowering blood glucose, increased excretion of urinary glucose, urinary glucose will rise. For patients with type 2 diabetes who have poor glycemic control through diet and exercise, dagliflozin can be chosen for monotherapy, or it can be used in combination with other hypoglycemic drugs, and when used in combination with other hypoglycemic drugs, attention should be paid to preventing hypoglycemia. The main side effects of Dagliflozin tablets are that they can cause symptomatic hypotension, ketoacidosis, kidney injury, and urinary tract infections. Dagliflozin tablets are contraindicated in patients with severe renal impairment (eGFR less than 30mL/min/1.73m2), end-stage renal disease (ESRD), or those requiring dialysis. Dagliflozin Tablet is a prescription drug, and it is recommended to take it according to the doctor’s instructions.